Introduction Executive Summary Recurrent anaplastic astrocytomas: Overview ● Causes ● Mechanism of Action ● Signs and Symptoms ● Diagnosis ● Disease Management Pipeline Therapeutics ● Comparative Analysis Therapeutic Assessment ● Assessment by Product Type ● Assessment by Stage and Product Type ● Assessment by Route of Administration ● Assessment by Stage and Route of Administration ● Assessment by Molecule Type ● Assessment by Stage and Molecule Type Recurrent anaplastic astrocytomas – DelveInsight’s Analytical Perspective In-depth Commercial Assessment ● Recurrent anaplastic astrocytomas companies’ collaborations, Licensing, Acquisition -Deal Value Trends Recurrent anaplastic astrocytomas Collaboration Deals ● Company-Company Collaborations (Licensing / Partnering) Analysis ● Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Preregistration) ● Comparative Analysis Eflornithine: Orbus Therapeutics, Inc. ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) ● Comparative Analysis Encorafenib: Pfizer ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) ● Comparative Analysis Fimepinostat: Curis, Inc. ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Preclinical Stage Products ● Comparative Analysis Drug Name: Company Name ● Product Description ● Research and Development ● Product Development Activities Drug profiles in the detailed report….. Inactive Products ● Comparative Analysis Recurrent anaplastic astrocytomas Key Companies Recurrent anaplastic astrocytomas Key Products Recurrent anaplastic astrocytomas- Unmet Needs Recurrent anaplastic astrocytomas- Market Drivers and Barriers Recurrent anaplastic astrocytomas- Future Perspectives and Conclusion Recurrent anaplastic astrocytomas Analyst Views Recurrent anaplastic astrocytomas Key Companies Appendix

Table 1 Total Products for Recurrent anaplastic astrocytomas Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Orbus Therapeutics • OncoSynergy, Inc. • Xenova Biomedix • Curis, Inc. • Hoffmann-La Roche